Progress in the treatment of breast cancer with histone deacetylase inhibitors
Author:
Affiliation:
Fund Project:
摘要
|
图/表
|
访问统计
|
参考文献
|
相似文献
|
引证文献
|
资源附件
|
文章评论
摘要:
伴随着组蛋白去乙酰化酶抑制剂（histone deacetylase inhibitor，HDACi）这一类靶向表观遗传调控机制的药物的创新发展，乳腺癌患者的治疗格局正在被逐渐改变。无论是激素受体（hormone receptor，HR）阳性且人表皮生长因子受体2（hu- man epidermal growth factor receptor 2，HER2）阴性乳腺癌患者还是三阴性乳腺癌（triple-negative breast cancer，TNBC）患者，都能够从HDACi联合治疗方案中取得可观的临床获益。文章围绕HDACi这一类药物，总结其在乳腺癌各个分子亚型中应用的研究进展，特别是总结了中国人群的治疗现状，对未来联合用药方案合理布局的探索进行综述。
Abstract:
With the innovative development of histone deacetylase inhibitors（HDACi），a class of drugs targeting epigenetic regulation mechanism，the treatment landscape for breast cancer patients is gradually changing. Both hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients，as well as triple-negative breast cancer（TNBC）patients，can benefit significantly from combination therapy with HDACi. This article summarizes the research progress of HDACi in various molecular subtypes of breast cancer，with a particular focus on the treatment status in the Chinese population and exploration of rational combination therapy strategies in the future.
